TVRD SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 31, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Tvardi Therapeutics Reports Q2 2026 Results and Selects Ulcerative Colitis as Initial Indication for TTI-109

Aug 14, 2026

8-K

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Jul 30, 2026

8-K

Tvardi Therapeutics Increases At-the-Market Offering Program

Jul 17, 2026

8-K

Tvardi Therapeutics Announces Positive Phase 1 Results for TTI-109

Jul 7, 2026

8-K

Tvardi Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 11, 2026

8-K

Tvardi Therapeutics Reports Q1 2026 Financial Results and Provides Clinical Development Updates

May 8, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

July 2026 ATM | Offering amount: $9,689,765 | Bank: JonesTrading Institutional Services LLC

Jul 17, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 2,084,117

Apr 1, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 2,084,117

Mar 6, 2026

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 2,084,117

Nov 13, 2025

425

Form 425 - Prospectuses and communications, business combinations

Mar 24, 2025

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Feb 14, 2025

Registrations

TYPE

HEADLINE

FILED AT

POS AM

Form POS AM - Post-Effective amendments for registration statement

May 8, 2026

S-3

May 2026 SHELF and ATM

May 1, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Apr 1, 2026

POS EX

Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]

Apr 1, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Oct 20, 2025

S-1/A

SHARE RESALE REGISTRATION | Shares amount: 2,084,117

Oct 20, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 22, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 22, 2024

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 12, 2024

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 20, 2023

Ownerships

TYPE

HEADLINE

FILED AT

Shiff Susan Ph.D. (Reporting)

Jun 11, 2026

Smith Cynthia (Reporting)

Jun 11, 2026

Shah Sujal (Reporting)

Jun 11, 2026

HALL WALLACE L JR (Reporting)

Jun 11, 2026

WYZGA MICHAEL S (Reporting)

Jun 11, 2026

S-3

Form S-3 - Registration statement under Securities Act of 1933

May 1, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

May 14, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

May 13, 2026

CORRESP

Form CORRESP - Correspondence

May 8, 2026

LETTER

Form UPLOAD - SEC-generated letter

May 7, 2026

LETTER

Form UPLOAD - SEC-generated letter

Jun 5, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 18, 2025

Tvardi Therapeutics, Inc. TVRD · SEC Filings